NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Anaptysbio, Inc. ANAB
11 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$234.6M
▲ 157.0% vs FY2024
EPS · FY25
$-0.46
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-24.5%
Net margin · FY25
-5.6%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 234.6M
Revenue, FY2025 · full 11-year series below
Revenue
Net income
The company lost 6 cents on every revenue dollar this year.
Per share
USD -0.46
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-24.5%
Return on equity, FY2025
ROE
Operating margin20.4%
Net margin-5.6%
Return on assets-3.1%
Each USD of equity lost 24 cents this year.
Returned to shareholders
USD 54.4M
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksUSD 54.4M
Share of profit-410.9%
Consecutive raises—
USD 54.4M in buybacks went back to shareholders in a year without profit.
Growth
+25.6% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+183.6%
+25.6%
+29.6%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.03B
Shares outstanding, FY2025
Change, 5 years+2.4%
Change, 10 years—
The share count grew 2% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 364.4M
total assets, end of FY2025
Total assetsUSD 364.4M
EquityUSD 37.2M
CashUSD 238.2M
Current ratio9.07×
Equity funds 10% of total assets.
History
11 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
Revenue $B
0.2
0.1
0.0
0.0
0.1
0.1
0.0
0.0
0.0
0.0
0.0
Operating income $B
0.0
−0.1
−0.2
−0.1
−0.1
−0.0
−0.1
−0.1
−0.0
−0.0
−0.0
EBITDA $B
0.0
−0.1
−0.2
−0.1
−0.1
−0.0
−0.1
−0.1
−0.0
−0.0
−0.0
Income tax $B
0.0
0.0
−0.0
0.0
0.0
0.0
−0.0
−0.0
0.0
0.0
0.0
Net income $B
−0.0
−0.1
−0.2
−0.1
−0.1
−0.0
−0.1
−0.1
−0.0
−0.0
−0.0
EPS, diluted $
−0.46
−5.12
−6.08
−4.57
−2.11
−0.73
−3.60
−2.50
−1.52
−1.62
−2.12
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
ROE %
−24.5
−182.7
−93.4
−41.6
−15.3
−5.0
−21.8
−15.5
−22.3
·
·
Shares out B
0.03
0.03
0.03
0.03
0.03
0.03
0.03
0.03
0.02
0.00
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
31 of 31
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed